Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scannerRoche's VENTANA DP 600 slide scanner received FDA clearance for aiding clinical diagnosis with digital images.
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHEREThe VENTANA FOLR1 RxDx Assay facilitates targeted treatment for ovarian cancer patients with ELAHERE, offering a crucial diagnostic tool in Europe.
The Key to Preserving a Long-Term Competitive AdvantageRoche and other pharma companies in Basel exemplify enduring competitive advantage through innovation.Transitioning from organic chemistry to microbiology has ensured the longevity of businesses in Basel.